Mylan Presses On With US Tecfidera Launch ‘At Risk’
Follows First FDA Approval For Rival To MS Blockbuster
Facing an appeal on a favorable US district court decision, Mylan has opted to launch the first generic Tecfidera in the US “at risk,” after obtaining FDA approval and seeing Biogen’s bid for injunctive relief shot down earlier this month.
